JP Morgan analyst Paul Coster downgrades Plexus (NASDAQ:PLXS) from Neutral to Underweight.
4D Molecular Therapeutics Announces $250M Proposed Public Offering Of Common Stock
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, announced today that it has